NICE recommends Medtronic integrated sensor-augmented insulin pump as the only therapy system to manage glucose levels in type 1 diabetes

12-February-2016

• The NICE guidance [2] reviewed two sensor-augmented insulin pump therapy systems and recommends the MiniMed Paradigm Veo system for managing glucose levels in people with Type 1 diabetes.[i]
• The MiniMed Paradigm Veo* sensor-augmented insulin pump therapy system can help to protect against severe hypoglycaemia in people with Type 1 diabetes by continuously monitoring glucose levels.[i]
• NICE recognised that in 2015, Medtronic launched a successor system, the MiniMed 640G**, which could be used in place of other reactive continuous glucose monitoring and insulin pump systems.[ii]
• Nearly 60,000 hospital admissions last year were as a result of severe hypoglycaemic attacks in people with Type 1 diabetes, costing the NHS approximately £55 million.[iii]
• Approximately one in three people with Type 1 diabetes have problematic hypoglycaemia, which can impact many aspects of daily life and result in substantial anxiety.[i]
• Up to 5,000 people with Type 1 diabetes could benefit from using continuous glucose monitoring (CGM).[i]
• NICE concluded that the adoption of Medtronic technology has the potential to save a UK health system £1,500 per person per year.[i]

CONTACT-US FORM